JP2017536092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536092A5 JP2017536092A5 JP2017517791A JP2017517791A JP2017536092A5 JP 2017536092 A5 JP2017536092 A5 JP 2017536092A5 JP 2017517791 A JP2017517791 A JP 2017517791A JP 2017517791 A JP2017517791 A JP 2017517791A JP 2017536092 A5 JP2017536092 A5 JP 2017536092A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hepatitis
- nucleic acid
- composition
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 claims description 116
- 239000000203 mixture Substances 0.000 claims description 90
- 241000700721 Hepatitis B virus Species 0.000 claims description 48
- 241000124008 Mammalia Species 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 108020004459 Small interfering RNA Proteins 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 34
- 208000029570 hepatitis D virus infection Diseases 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 32
- 208000002672 hepatitis B Diseases 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 150000002632 lipids Chemical class 0.000 claims description 21
- 230000030279 gene silencing Effects 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 150000003904 phospholipids Chemical class 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- -1 cationic lipid Chemical class 0.000 claims description 12
- 208000037262 Hepatitis delta Diseases 0.000 claims description 11
- 241000724709 Hepatitis delta virus Species 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 230000009885 systemic effect Effects 0.000 claims description 8
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 6
- 238000004220 aggregation Methods 0.000 claims description 6
- 230000002776 aggregation Effects 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- ARJCMRWHZPDQJG-ASSJVFBPSA-N [(6z,16z)-12-[(z)-dec-4-enyl]docosa-6,16-dien-11-yl] 5-(dimethylamino)pentanoate Chemical compound CCCCC\C=C/CCCC(CCC\C=C/CCCCC)C(CCC\C=C/CCCCC)OC(=O)CCCCN(C)C ARJCMRWHZPDQJG-ASSJVFBPSA-N 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- VHRYAHCCVUHIBM-NSOMFCEZSA-N n,n-dimethyl-1,2-bis[(6z,9z,12z)-octadeca-6,9,12-trienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCOC(C)C(N(C)C)OCCCCC\C=C/C\C=C/C\C=C/CCCCC VHRYAHCCVUHIBM-NSOMFCEZSA-N 0.000 claims description 2
- XVUQPECVOGMPRU-ZPPAUJSGSA-N n,n-dimethyl-1,2-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC XVUQPECVOGMPRU-ZPPAUJSGSA-N 0.000 claims description 2
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059056P | 2014-10-02 | 2014-10-02 | |
| US62/059,056 | 2014-10-02 | ||
| US201562120149P | 2015-02-24 | 2015-02-24 | |
| US62/120,149 | 2015-02-24 | ||
| PCT/US2015/053569 WO2016054421A1 (en) | 2014-10-02 | 2015-10-01 | Compositions and methods for silencing hepatitis b virus gene expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536092A JP2017536092A (ja) | 2017-12-07 |
| JP2017536092A5 true JP2017536092A5 (cg-RX-API-DMAC7.html) | 2018-03-15 |
Family
ID=54325078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517791A Pending JP2017536092A (ja) | 2014-10-02 | 2015-10-01 | Ｂ型肝炎ウイルスの遺伝子発現をサイレンシングするための組成物及び方法 |
Country Status (17)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5475753B2 (ja) * | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | 核酸送達用の脂質製剤 |
| CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| EP2717893B1 (en) | 2011-06-08 | 2019-05-08 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| TR201901310T4 (tr) | 2013-03-14 | 2019-02-21 | Translate Bio Inc | Mesajcı RNA'nın saflaştırılması yöntemleri. |
| JP6399560B2 (ja) | 2013-03-14 | 2018-10-03 | トランスレイト バイオ， インコーポレイテッド | ｍＲＮＡによってコードされる抗体を送達するための方法及び組成物 |
| LT2968586T (lt) | 2013-03-14 | 2018-11-26 | Translate Bio, Inc. | Cft mrnr kompozicijos bei su jomis susiję būdai ir panaudojimai |
| DK2972360T3 (en) | 2013-03-15 | 2018-05-22 | Translate Bio Inc | SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS THROUGH MIXED FORMULATIONS |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| BR112016009014B1 (pt) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc | USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE |
| CN105658800A (zh) | 2013-10-22 | 2016-06-08 | 夏尔人类遗传性治疗公司 | Mrna的cns递送及其用途 |
| CN112618732A (zh) | 2013-10-22 | 2021-04-09 | 夏尔人类遗传性治疗公司 | 用于递送信使rna的脂质制剂 |
| KR102739894B1 (ko) | 2014-04-25 | 2024-12-05 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| US10022455B2 (en) | 2014-05-30 | 2018-07-17 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| CN111588695A (zh) | 2014-06-24 | 2020-08-28 | 川斯勒佰尔公司 | 用于递送核酸的立体化学富集组合物 |
| BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| WO2016090262A1 (en) | 2014-12-05 | 2016-06-09 | Shire Human Genetic Therapies, Inc. | Messenger rna therapy for treatment of articular disease |
| AU2016233135B2 (en) | 2015-03-19 | 2021-07-08 | Translate Bio, Inc. | mRNA therapy for pompe disease |
| US20170016000A1 (en) | 2015-07-17 | 2017-01-19 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| WO2017019891A2 (en) * | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
| CA3001852A1 (en) | 2015-10-14 | 2017-04-20 | Translate Bio, Inc. | Modification of rna-related enzymes for enhanced production |
| WO2017177169A1 (en) | 2016-04-08 | 2017-10-12 | Rana Therapeutics, Inc. | Multimeric coding nucleic acid and uses thereof |
| EP3842530A1 (en) | 2016-06-13 | 2021-06-30 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
| AU2017353986B2 (en) * | 2016-11-07 | 2021-08-19 | Arbutus Biopharma Corporation | Substituted pyridinone-containing tricyclic compounds, and methods using same |
| JP7325327B2 (ja) * | 2016-12-21 | 2023-08-14 | アルブータス・バイオファーマー・コーポレイション | インフュージョンリアクションを改善するための方法 |
| EP3585417B1 (en) | 2017-02-27 | 2023-02-22 | Translate Bio, Inc. | Method of making a codon-optimized cftr mrna |
| CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| TW201919653A (zh) * | 2017-06-16 | 2019-06-01 | 加拿大商艾爾布圖斯生技公司 | 用於治療ｂ型肝炎之治療組合物及方法 |
| CN109101120B (zh) * | 2017-06-21 | 2021-09-28 | 腾讯科技（深圳）有限公司 | 图像显示的方法和装置 |
| WO2019051257A2 (en) * | 2017-09-11 | 2019-03-14 | Arbutus Biopharma Corporation | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
| CR20210262A (es) | 2017-10-16 | 2022-06-27 | Hoffmann La Roche | MOLÉCULA DE ÁCIDOS NUCLEICOS PARA LA REDUCCIÓN DEL ARNm DE PAPD5 Y PAPD7 EN EL TRATAMIENTO DE LA INFECCIÓN DE LA HEPATITIS B (DIVISIONAL DEL EXPEDIENTE 2020-0205) |
| MA51306A (fr) | 2017-12-20 | 2020-10-28 | Translate Bio Inc | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase |
| TWI801517B (zh) | 2018-03-12 | 2023-05-11 | 加拿大商愛彼特生物製藥公司 | 經取代的2-吡啶酮三環化合物、其類似物及其使用方法 |
| RU2020135289A (ru) * | 2018-04-05 | 2022-05-05 | Ф. Хоффманн-Ля Рош Аг | Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в |
| JP2021521154A (ja) | 2018-04-12 | 2021-08-26 | アービュタス バイオファーマ コーポレイション | 置換ピリジノン含有三環式化合物を調製するための方法 |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| US20210395751A1 (en) * | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| WO2020097540A1 (en) | 2018-11-09 | 2020-05-14 | Arbutus Biopharma Corporation | Lipid nanoparticle formulations |
| AU2019377131A1 (en) * | 2018-11-09 | 2021-06-03 | Arbutus Biopharma Corporation | Lipid nanoparticle formulations |
| CA3120647A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr |
| WO2020136149A1 (en) | 2018-12-24 | 2020-07-02 | Selexis Sa | Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells |
| US20230046668A1 (en) | 2019-12-24 | 2023-02-16 | Selexis S.A. | Targeted integration in mammalian sequences enhancing gene expression |
| RU2733361C1 (ru) * | 2020-07-14 | 2020-10-01 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией |
| RU2746362C9 (ru) * | 2021-03-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Комбинированное лекарственное средство, обладающее противовирусным эффектом в отношении нового коронавируса SARS-CoV-2 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| CH624011A5 (cg-RX-API-DMAC7.html) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| WO1993023011A1 (en) | 1992-05-18 | 1993-11-25 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| CA2200952C (en) | 1994-09-30 | 2006-04-11 | Inex Pharmaceuticals Corp. | Novel compositions comprising quaternary ammonium compounds and neutral lipids for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| AU723163B2 (en) | 1995-06-07 | 2000-08-17 | Tekmira Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| IL115199A (en) | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| US6756054B1 (en) | 1996-05-24 | 2004-06-29 | Ic-Vec Limited | Polycationic sterol derivatives as transfection agents |
| DE69725878T2 (de) | 1996-08-13 | 2004-07-29 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Zusammensetzungen zur polynukleotidabgabe |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| US20030229040A1 (en) | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
| DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| DE69834038D1 (de) | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| JP2001510808A (ja) | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
| US6110745A (en) | 1997-07-24 | 2000-08-29 | Inex Pharmaceuticals Corp. | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
| ATE237312T1 (de) | 1998-07-20 | 2003-05-15 | Protiva Biotherapeutics Inc | In liposomen verkapselte nukleinsäurekomplexe |
| US7479276B1 (en) | 1999-02-22 | 2009-01-20 | Synergene Therapeutics, Inc. | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| EP1173600A2 (en) | 1999-04-20 | 2002-01-23 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| US6852334B1 (en) | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| US6200599B1 (en) | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
| US20050037086A1 (en) | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
| WO2001072283A1 (en) | 2000-03-29 | 2001-10-04 | Aradigm Corporation | Cationic liposomes |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| AU6815901A (en) | 2000-06-02 | 2001-12-17 | Zycos Inc | Delivery systems for bioactive agents |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| AU2002305094B2 (en) | 2001-03-26 | 2007-01-11 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
| WO2002076427A2 (en) | 2001-03-26 | 2002-10-03 | Thomas Jefferson University | Ph sensitive liposomal drug delivery |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| US20030203865A1 (en) | 2001-04-30 | 2003-10-30 | Pierrot Harvie | Lipid-comprising drug delivery complexes and methods for their production |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| DE10127526A1 (de) | 2001-05-31 | 2002-12-12 | Novosom Ag | Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln |
| US7063860B2 (en) | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| DE10152145A1 (de) | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
| US20030157030A1 (en) | 2001-11-02 | 2003-08-21 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
| DE10157046A1 (de) | 2001-11-18 | 2003-06-12 | Novosom Ag | Nano- und Mikrokapseln umfassend Reaktivpolymere |
| WO2003057190A1 (en) | 2001-12-31 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| US20060058249A1 (en) | 2002-01-09 | 2006-03-16 | Shangguan Tong | Efficient nucleic acid encapsulation into medium sized liposomes |
| US20060051315A1 (en) | 2002-02-01 | 2006-03-09 | Scaria Puthupparampil V | Polymers for delivering peptides and small molecules in vivo |
| DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| EP1476492A1 (en) | 2002-02-22 | 2004-11-17 | Insert Therapeutics Inc. | Carbohydrate-modified polymers, compositions and uses related thereto |
| US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| US20030198664A1 (en) | 2002-03-29 | 2003-10-23 | Sullivan Sean Michael | Lipid mediated screening of drug candidates for identification of active compounds |
| EP1507561B1 (en) | 2002-05-24 | 2009-07-15 | Mirus Bio Corporation | Compositions for delivering nucleic acids to cells |
| DE60335186D1 (de) | 2002-06-20 | 2011-01-13 | Cytos Biotechnology Ag | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
| EP2338478B1 (en) | 2002-06-28 | 2014-07-23 | Protiva Biotherapeutics Inc. | Method for producing liposomes |
| US7682626B2 (en) | 2003-02-07 | 2010-03-23 | Roche Madison Inc. | Polyvinylethers for delivery of polynucleotides to mammalian cells |
| JP4951338B2 (ja) | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質に封入された干渉ｒｎａ |
| JP4842821B2 (ja) | 2003-09-15 | 2011-12-21 | プロチバ バイオセラピューティクス インコーポレイティッド | ポリエチレングリコール修飾脂質化合物およびその使用 |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| US7883688B2 (en) | 2005-02-03 | 2011-02-08 | Agency For Science, Technology And Research | Polycationic polyrotaxanes capable of forming complexes with nucleic acids |
| WO2007086881A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| EP1937213B1 (en) | 2005-07-27 | 2017-10-25 | Protiva Biotherapeutics Inc. | Systems and methods for manufacturing liposomes |
| CN105030654A (zh) | 2006-10-03 | 2015-11-11 | 阿尔尼拉姆医药品有限公司 | 含脂质的制品 |
| KR101629017B1 (ko) | 2007-05-22 | 2016-06-10 | 아크투루스 쎄라퓨틱스, 인크. | 히드록시메틸 치환된 ｒｎａ 올리고뉴클레오티드 및 ｒｎａ 복합체 |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| JP5475753B2 (ja) | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | 核酸送達用の脂質製剤 |
| CN101603042B (zh) * | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| WO2010006282A2 (en) | 2008-07-10 | 2010-01-14 | Serina Therapeutics, Inc. | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
| CA2744093A1 (en) | 2008-12-03 | 2010-06-10 | Marina Biotech, Inc. | Una oligomer structures for therapeutic agents |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| WO2011139710A1 (en) | 2010-04-26 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
| HUE044815T2 (hu) * | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
| WO2013003520A1 (en) | 2011-06-30 | 2013-01-03 | Arrowhead Research Corporation | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
-
2015
- 2015-10-01 BR BR112017006679A patent/BR112017006679A2/pt not_active Application Discontinuation
- 2015-10-01 CR CR20170174A patent/CR20170174A/es unknown
- 2015-10-01 EP EP15781007.8A patent/EP3201338B1/en active Active
- 2015-10-01 US US15/515,952 patent/US10415037B2/en active Active
- 2015-10-01 KR KR1020177011725A patent/KR20170075742A/ko not_active Withdrawn
- 2015-10-01 AU AU2015328012A patent/AU2015328012A1/en not_active Abandoned
- 2015-10-01 WO PCT/US2015/053569 patent/WO2016054421A1/en not_active Ceased
- 2015-10-01 CA CA2963271A patent/CA2963271A1/en not_active Abandoned
- 2015-10-01 JP JP2017517791A patent/JP2017536092A/ja active Pending
- 2015-10-01 CN CN201580062374.9A patent/CN107208095B/zh active Active
- 2015-10-01 SG SG11201702662UA patent/SG11201702662UA/en unknown
- 2015-10-01 RU RU2017114964A patent/RU2017114964A/ru not_active Application Discontinuation
- 2015-10-02 TW TW107110295A patent/TW201900876A/zh unknown
- 2015-10-02 TW TW104132625A patent/TW201623614A/zh unknown
-
2017
- 2017-03-29 IL IL251450A patent/IL251450A0/en unknown
- 2017-03-31 CL CL2017000780A patent/CL2017000780A1/es unknown
- 2017-04-03 PH PH12017500614A patent/PH12017500614A1/en unknown
- 2017-04-27 CO CONC2017/0004290A patent/CO2017004290A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536092A5 (cg-RX-API-DMAC7.html) | ||
| CN107208095B (zh) | 用于使乙型肝炎病毒基因表达沉默的组合物和方法 | |
| JP7086870B2 (ja) | メッセンジャーｒｎａを送達するための組成物及び方法 | |
| JP5475753B2 (ja) | 核酸送達用の脂質製剤 | |
| JP5766188B2 (ja) | 固形腫瘍に治療剤を送達するための脂質製剤 | |
| JP5977394B2 (ja) | 脂質に封入された干渉ｒｎａ | |
| JP2016525146A5 (cg-RX-API-DMAC7.html) | ||
| JP7150608B2 (ja) | 多量体コード核酸及びその使用 | |
| US20180245074A1 (en) | Treating hepatitis b virus infection using crispr | |
| WO2016071857A1 (en) | Compositions and methods for silencing ebola virus expression | |
| JP2014530602A5 (cg-RX-API-DMAC7.html) | ||
| CN105555757A (zh) | 用于递送信使rna的组合物和方法 | |
| JP7325327B2 (ja) | インフュージョンリアクションを改善するための方法 | |
| TW201718856A (zh) | 用於使b型肝炎病毒基因表現沈默之組合物及方法 | |
| BR112021008953A2 (pt) | partículas de ácido nucleico-lipídio e de ácido-lipídio, composições, métodos para introduzir um ácido nucleico em uma célula, para distribuição in vivo de um ácido nucleico, para tratar uma doença ou um distúrbio e para preparar um composto, usos de uma partícula, compostos e nanopartícula de lipídio | |
| JP2011516094A5 (cg-RX-API-DMAC7.html) | ||
| TW201919653A (zh) | 用於治療ｂ型肝炎之治療組合物及方法 | |
| CN110022895A (zh) | 用于治疗乙型肝炎的治疗组合物和方法 | |
| CN117177738A (zh) | 通过混合的阳离子性脂质颗粒的组织特异性核酸递送 | |
| JP2024534066A (ja) | 脂質ナノ粒子製剤 | |
| EP4251598A2 (en) | Long-acting and long-circulating delivery vehicles | |
| US20220184113A1 (en) | RATIONALLY DESIGNED ANTIVIRAL COMPOUNDS THAT INHIBIT SARS-CoV-2 AND THEIR METHODS OF USE THEREOF | |
| WO2022147304A1 (en) | Compositions and methods for treating metabolic disorders | |
| EA050406B1 (ru) | Катионные липиды, содержащие кремний | |
| HK1245271B (zh) | 胺阳离子脂质及其用途 |